Advice

following a full submission:

nivolumab (Opdivo®) is accepted for use within NHSScotland.

Indication under review: As monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

Adjuvant treatment with nivolumab improved recurrence free survival compared with another immunotherapy in adults with melanoma with involvement of lymph nodes or metastatic disease who had undergone complete resection.

SMC advice takes account of the benefit of Patient Access Schemes (PAS) that improve the cost effectiveness of nivolumab and is contingent upon the continuing availability of this PAS in NHSScotland or a list price that is equivalent or lower.

Medicine details

Medicine name:
nivolumab (Opdivo)
SMC ID:
SMC2112
Indication:
as monotherapy is indicated for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Accepted
Date advice published:
10 December 2018